MIT Technology Review March 10, 2023
Jessica Hamzelou

But at a global genome-editing summit, exciting trial results were tempered by safety and ethical concerns.

I’ve spent the last few days thinking about how, when, and if we should use gene-editing tools to change the human genome. These are huge questions, and very emotive ones—especially when it comes to editing embryos.

I watched scientists, ethicists, patient advocacy groups, and others wrestle with these topics at the Third International Summit on Human Genome Editing in London earlier this week.

There’s plenty to get excited about when it comes to gene editing. In the decade since scientists found they could use CRISPR to edit...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Clinical Trials, Pharma / Biotech, Trends
Boehringer signs $1.3B deal with RNA biotech Ochre Bio to team up against MASH
Bristol Myers taps startup to boost cell therapy production
With $380M deal, Bristol Myers Squibb ups the ante with cell therapy manufacturer Cellares
Boehringer Ingelheim Strikes Regenerative Med R&D Deal Spanning MASH & More Liver Diseases
Metsera Launches with $290M to Develop Next Generation Weight Loss Products

Share This Article